No Cover Image

Journal article 253 views 46 downloads

Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion

Ruochen Zang, James Brett Case, Eylan Yutuc Orcid Logo, Xiucui Ma, Sheng Shen, Maria Florencia Gomez Castro, Zhuoming Liu, Qiru Zeng, Haiyan Zhao, Juhee Son, Paul W. Rothlauf, Alex J. B. Kreutzberger, Gaopeng Hou, Hu Zhang, Sayantan Bose, Xin Wang, Michael D. Vahey, Kartik Mani, William Griffiths Orcid Logo, Tom Kirchhausen, Daved H. Fremont, Haitao Guo, Abhinav Diwan, Yuqin Wang Orcid Logo, Michael S. Diamond, Sean P. J. Whelan, Siyuan Ding

Proceedings of the National Academy of Sciences, Volume: 117, Issue: 50, Pages: 32105 - 32113

Swansea University Authors: Eylan Yutuc Orcid Logo, William Griffiths Orcid Logo, Yuqin Wang Orcid Logo

  • 2012197117.full.pdf

    PDF | Version of Record

    This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).

    Download (1.41MB)

Abstract

The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiological agent of coronavirus disease-2019 (COVID-19), has swept the world in unprecedented speed. In a few months, SARS-CoV-2 has infected millions of people and caused tens of thousands of deaths. There are no Food and...

Full description

Published in: Proceedings of the National Academy of Sciences
ISSN: 0027-8424 1091-6490
Published: Proceedings of the National Academy of Sciences 2020
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa55583
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2020-11-03T09:39:41Z
last_indexed 2020-12-22T04:18:54Z
id cronfa55583
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2020-12-21T13:27:56.2040669</datestamp><bib-version>v2</bib-version><id>55583</id><entry>2020-11-03</entry><title>Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion</title><swanseaauthors><author><sid>99332f073ce913a9b7d8b6441b17516d</sid><ORCID>0000-0001-9971-1950</ORCID><firstname>Eylan</firstname><surname>Yutuc</surname><name>Eylan Yutuc</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>3316b1d1b524be1831790933eed1c26e</sid><ORCID>0000-0002-4129-6616</ORCID><firstname>William</firstname><surname>Griffiths</surname><name>William Griffiths</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>c92729b58622f9fdf6a0e7d8f4ce5081</sid><ORCID>0000-0002-3063-3066</ORCID><firstname>Yuqin</firstname><surname>Wang</surname><name>Yuqin Wang</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2020-11-03</date><deptcode>BMS</deptcode><abstract>The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiological agent of coronavirus disease-2019 (COVID-19), has swept the world in unprecedented speed. In a few months, SARS-CoV-2 has infected millions of people and caused tens of thousands of deaths. There are no Food and Drug Administration-approved antivirals or vaccines yet available and clinical treatments are limited to supportive therapies that help alleviate the symptoms. Thus, there is an urgent need to identify effective antivirals as countermeasures before safe and effective vaccines are developed, tested, and then produced on a large scale. Our approach is to harness the germline-encoded interferon antiviral response to inhibit SARS-CoV-2 replication thereby limiting its pathogenicity</abstract><type>Journal Article</type><journal>Proceedings of the National Academy of Sciences</journal><volume>117</volume><journalNumber>50</journalNumber><paginationStart>32105</paginationStart><paginationEnd>32113</paginationEnd><publisher>Proceedings of the National Academy of Sciences</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>0027-8424</issnPrint><issnElectronic>1091-6490</issnElectronic><keywords>SARS-CoV-2; interferon; virus entry; COVID-19; innate immunity</keywords><publishedDay>15</publishedDay><publishedMonth>12</publishedMonth><publishedYear>2020</publishedYear><publishedDate>2020-12-15</publishedDate><doi>10.1073/pnas.2012197117</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2020-12-21T13:27:56.2040669</lastEdited><Created>2020-11-03T09:35:52.5261441</Created><path><level id="1">Swansea University Medical School</level><level id="2">Medicine</level></path><authors><author><firstname>Ruochen</firstname><surname>Zang</surname><order>1</order></author><author><firstname>James Brett</firstname><surname>Case</surname><order>2</order></author><author><firstname>Eylan</firstname><surname>Yutuc</surname><orcid>0000-0001-9971-1950</orcid><order>3</order></author><author><firstname>Xiucui</firstname><surname>Ma</surname><order>4</order></author><author><firstname>Sheng</firstname><surname>Shen</surname><order>5</order></author><author><firstname>Maria Florencia Gomez</firstname><surname>Castro</surname><order>6</order></author><author><firstname>Zhuoming</firstname><surname>Liu</surname><order>7</order></author><author><firstname>Qiru</firstname><surname>Zeng</surname><order>8</order></author><author><firstname>Haiyan</firstname><surname>Zhao</surname><order>9</order></author><author><firstname>Juhee</firstname><surname>Son</surname><order>10</order></author><author><firstname>Paul W.</firstname><surname>Rothlauf</surname><order>11</order></author><author><firstname>Alex J. B.</firstname><surname>Kreutzberger</surname><order>12</order></author><author><firstname>Gaopeng</firstname><surname>Hou</surname><order>13</order></author><author><firstname>Hu</firstname><surname>Zhang</surname><order>14</order></author><author><firstname>Sayantan</firstname><surname>Bose</surname><order>15</order></author><author><firstname>Xin</firstname><surname>Wang</surname><order>16</order></author><author><firstname>Michael D.</firstname><surname>Vahey</surname><order>17</order></author><author><firstname>Kartik</firstname><surname>Mani</surname><order>18</order></author><author><firstname>William</firstname><surname>Griffiths</surname><orcid>0000-0002-4129-6616</orcid><order>19</order></author><author><firstname>Tom</firstname><surname>Kirchhausen</surname><order>20</order></author><author><firstname>Daved H.</firstname><surname>Fremont</surname><order>21</order></author><author><firstname>Haitao</firstname><surname>Guo</surname><order>22</order></author><author><firstname>Abhinav</firstname><surname>Diwan</surname><order>23</order></author><author><firstname>Yuqin</firstname><surname>Wang</surname><orcid>0000-0002-3063-3066</orcid><order>24</order></author><author><firstname>Michael S.</firstname><surname>Diamond</surname><order>25</order></author><author><firstname>Sean P. J.</firstname><surname>Whelan</surname><order>26</order></author><author><firstname>Siyuan</firstname><surname>Ding</surname><order>27</order></author></authors><documents><document><filename>55583__18748__27bea0901ce147f187d37525e9014901.pdf</filename><originalFilename>2012197117.full.pdf</originalFilename><uploaded>2020-11-26T08:45:38.2353401</uploaded><type>Output</type><contentLength>1477724</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2020-12-21T13:27:56.2040669 v2 55583 2020-11-03 Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion 99332f073ce913a9b7d8b6441b17516d 0000-0001-9971-1950 Eylan Yutuc Eylan Yutuc true false 3316b1d1b524be1831790933eed1c26e 0000-0002-4129-6616 William Griffiths William Griffiths true false c92729b58622f9fdf6a0e7d8f4ce5081 0000-0002-3063-3066 Yuqin Wang Yuqin Wang true false 2020-11-03 BMS The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiological agent of coronavirus disease-2019 (COVID-19), has swept the world in unprecedented speed. In a few months, SARS-CoV-2 has infected millions of people and caused tens of thousands of deaths. There are no Food and Drug Administration-approved antivirals or vaccines yet available and clinical treatments are limited to supportive therapies that help alleviate the symptoms. Thus, there is an urgent need to identify effective antivirals as countermeasures before safe and effective vaccines are developed, tested, and then produced on a large scale. Our approach is to harness the germline-encoded interferon antiviral response to inhibit SARS-CoV-2 replication thereby limiting its pathogenicity Journal Article Proceedings of the National Academy of Sciences 117 50 32105 32113 Proceedings of the National Academy of Sciences 0027-8424 1091-6490 SARS-CoV-2; interferon; virus entry; COVID-19; innate immunity 15 12 2020 2020-12-15 10.1073/pnas.2012197117 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University 2020-12-21T13:27:56.2040669 2020-11-03T09:35:52.5261441 Swansea University Medical School Medicine Ruochen Zang 1 James Brett Case 2 Eylan Yutuc 0000-0001-9971-1950 3 Xiucui Ma 4 Sheng Shen 5 Maria Florencia Gomez Castro 6 Zhuoming Liu 7 Qiru Zeng 8 Haiyan Zhao 9 Juhee Son 10 Paul W. Rothlauf 11 Alex J. B. Kreutzberger 12 Gaopeng Hou 13 Hu Zhang 14 Sayantan Bose 15 Xin Wang 16 Michael D. Vahey 17 Kartik Mani 18 William Griffiths 0000-0002-4129-6616 19 Tom Kirchhausen 20 Daved H. Fremont 21 Haitao Guo 22 Abhinav Diwan 23 Yuqin Wang 0000-0002-3063-3066 24 Michael S. Diamond 25 Sean P. J. Whelan 26 Siyuan Ding 27 55583__18748__27bea0901ce147f187d37525e9014901.pdf 2012197117.full.pdf 2020-11-26T08:45:38.2353401 Output 1477724 application/pdf Version of Record true This open access article is distributed under Creative Commons Attribution License 4.0 (CC BY). true eng http://creativecommons.org/licenses/by/4.0/
title Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
spellingShingle Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
Eylan Yutuc
William Griffiths
Yuqin Wang
title_short Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
title_full Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
title_fullStr Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
title_full_unstemmed Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
title_sort Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
author_id_str_mv 99332f073ce913a9b7d8b6441b17516d
3316b1d1b524be1831790933eed1c26e
c92729b58622f9fdf6a0e7d8f4ce5081
author_id_fullname_str_mv 99332f073ce913a9b7d8b6441b17516d_***_Eylan Yutuc
3316b1d1b524be1831790933eed1c26e_***_William Griffiths
c92729b58622f9fdf6a0e7d8f4ce5081_***_Yuqin Wang
author Eylan Yutuc
William Griffiths
Yuqin Wang
author2 Ruochen Zang
James Brett Case
Eylan Yutuc
Xiucui Ma
Sheng Shen
Maria Florencia Gomez Castro
Zhuoming Liu
Qiru Zeng
Haiyan Zhao
Juhee Son
Paul W. Rothlauf
Alex J. B. Kreutzberger
Gaopeng Hou
Hu Zhang
Sayantan Bose
Xin Wang
Michael D. Vahey
Kartik Mani
William Griffiths
Tom Kirchhausen
Daved H. Fremont
Haitao Guo
Abhinav Diwan
Yuqin Wang
Michael S. Diamond
Sean P. J. Whelan
Siyuan Ding
format Journal article
container_title Proceedings of the National Academy of Sciences
container_volume 117
container_issue 50
container_start_page 32105
publishDate 2020
institution Swansea University
issn 0027-8424
1091-6490
doi_str_mv 10.1073/pnas.2012197117
publisher Proceedings of the National Academy of Sciences
college_str Swansea University Medical School
hierarchytype
hierarchy_top_id swanseauniversitymedicalschool
hierarchy_top_title Swansea University Medical School
hierarchy_parent_id swanseauniversitymedicalschool
hierarchy_parent_title Swansea University Medical School
department_str Medicine{{{_:::_}}}Swansea University Medical School{{{_:::_}}}Medicine
document_store_str 1
active_str 0
description The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiological agent of coronavirus disease-2019 (COVID-19), has swept the world in unprecedented speed. In a few months, SARS-CoV-2 has infected millions of people and caused tens of thousands of deaths. There are no Food and Drug Administration-approved antivirals or vaccines yet available and clinical treatments are limited to supportive therapies that help alleviate the symptoms. Thus, there is an urgent need to identify effective antivirals as countermeasures before safe and effective vaccines are developed, tested, and then produced on a large scale. Our approach is to harness the germline-encoded interferon antiviral response to inhibit SARS-CoV-2 replication thereby limiting its pathogenicity
published_date 2020-12-15T04:10:43Z
_version_ 1737027636668923904
score 10.8781185